Diltiazem

Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics

Retrieved on: 
Wednesday, April 6, 2022
Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Risk, Hypoglycemia, Therapy, Meropenem, First-degree atrioventricular block, Clonidine, Blood pressure, Cardiac arrest, NYHA, III, Allergy, Moyamoya disease, Diabetes, Angina, Diltiazem, Hyperthyroidism, Vaborbactam, Cardiogenic shock, AstraZeneca, Heart, Patient, Hypertension, Bradycardia, Peripheral artery disease, CEO, Adrenaline, Sinus node dysfunction, Pheochromocytoma, LLC, Heart block, Acquisition, Stroke, Verapamil, Injection, Castleman disease, Heart failure, Purkinje fibers, Digitalis, FDA, Minocycline, Infarction, Hypersensitivity, Pharmaceutical industry, Medical device, Melinta Therapeutics

We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.

Key Points: 
  • We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.
  • We are extremely proud of our work to provide access to this lifesaving medication, said Michael Anderson, CEO, New American Therapeutics.
  • Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses.
  • At Melinta, were visionaries dedicated to innovation while staying grounded in what matters most: patients.

Advisory - All strengths of MAR-Diltiazem CD, a drug used to treat angina and hypertension, have been recalled because of dosing concerns

Retrieved on: 
Friday, September 25, 2020
Articles, Organic compounds, Health, RTT, Lactams, Diltiazem, Generic drug, Bioequivalence

What to do: Patients using MAR-Diltiazem CD should consult with their doctor or pharmacist as soon as possible to find an alternative product.

Key Points: 
  • What to do: Patients using MAR-Diltiazem CD should consult with their doctor or pharmacist as soon as possible to find an alternative product.
  • Health Canada is informing Canadians that Marcan Pharmaceuticals has recalled all lots of all MAR-Diltiazem CD products in response to data integrity concerns that could lead to incorrect dosing.
  • MAR-Diltiazem CD is used to treat chronic stable angina and mild to moderate hypertension.
  • Bioequivalence studies are used to demonstrate that a generic drug produces the same amount of active ingredient in the blood as a brand-name drug.